Moderna Stock News

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to prevent lower respiratory tract disease caused by RSV infection in adults aged 60 years and older.1 mRESVIA's approval marks a significant mil...

Valuation always matters in investing. And sometimes you can find stocks that are especially great bargains.

Moderna stock skidded on reports Robert F. Kennedy Jr. is considering pulling funding for its bird flu vaccine.

It's been nearly five years since Moderna (MRNA -1.60%) emerged as a biotech industry disruptor, with its COVID-19 vaccine playing a landmark role in tackling the global pandemic in late 2020. Despite its generating record sales and profits through 2022, early projections of sustained demand for coronavirus vaccinations failed to materialize, leading to a sharp drop in the business.

Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech stock might soar as investors bet on the company's cutting-edge technology through its development stages -- and the stock could continue to gain after that company moves into the product commercialization stage.

Dublin, March 18, 2025 (GLOBE NEWSWIRE) -- The "mRNA Vaccines Market by Technology Type, Route of Administration, Manufacturing Process, Vaccine Classification, Application Areas, End-User, Distribution Channel - Global Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering. The mRNA Vaccines Market grew from USD 9.32 billion in 2024 to USD 10.40 billion in 2025. It is e...

As we near the five-year anniversary of the COVID-19 pandemic, it's a good time to revisit the drugmaker stock that was top of mind back then. A few years ago, Moderna (MRNA 0.93%) stock soared on the back of the highly successful vaccine it developed in record time.

Difficult-to-short stocks are often greatly overvalued.